PCM
MYGN icon

Piermont Capital Management’s Myriad Genetics MYGN Stock Holding History

Piermont Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-42,660
Closed -$878K – 263
2016
Q3 		$878K Buy
42,660
+9,410
+28% +$239K 0.21% 179
2016
Q2 		$1.02M Buy
33,250
+17,225
+107% +$598K 0.26% 142
2016
Q1 		$600K Buy
16,025
+385
+2% +$14.5K 0.19% 127
2015
Q4 		$675K Buy
+15,640
New +$661K 0.21% 114

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Piermont Capital Management's MYGN Position: Q4 2016 in Review

Piermont Capital Management sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 42,660 shares — an estimated $878K sold.

Piermont Capital Management first reported a position in MYGN in Q4 2015 and held it in 4 quarters. The position peaked at $1.02M in Q2 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • Piermont Capital Management reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
  • Piermont Capital Management sold 42,660 Myriad Genetics shares in Q4 2016, an estimated $878K.
  • Piermont Capital Management first reported a position in Myriad Genetics in Q4 2015 and held it in 4 quarters.
  • Piermont Capital Management's Myriad Genetics position peaked at $1.02M in Q2 2016.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Piermont Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.